Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Consensus Target Price of $32.43

Key Points

• Analyst sentiment is mixed: Sixteen firms rate Hims & Hers Health “Hold” overall, with 12 holds, three buys and one sell. The consensus 12-month price target is $32.43.
• Revenue growth outweighed a significant earnings miss: Quarterly revenue rose 38.2% year over year to $753.2 million, but adjusted earnings of negative $0.37 per share missed estimates by $0.32. Analysts expect the company to remain unprofitable for the full year.
• Legal and regulatory risks remain important concerns: A proposed securities-fraud class action tied to alleged privacy, subscription-cancellation and prescription-billing issues could create costs and reputational damage, while the company is also launching an AI-powered weight-loss platform aimed at improving personalization and retention.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) has earned a consensus rating of "Hold" from the sixteen research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $32.43.

Several research analysts have commented on HIMS shares. TD Cowen upped their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. Morgan Stanley lifted their price target on Hims & Hers Health from $21.00 to $28.00 and gave the company an "equal weight" rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft boosted their price objective on Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. Barclays decreased their price objective on Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating for the company in a report on Friday, August 21st. Finally, Needham & Company LLC raised their target price on Hims & Hers Health from $35.00 to $42.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers launched an AI-native weight-loss care platform featuring a closed-loop action engine and clinical escalation. The initiative could improve treatment personalization, operating efficiency and customer retention, although its financial impact has not yet been quantified. AI-native weight-loss platform article
• Neutral Sentiment: CFO Oluyemi Okupe sold 29,277 shares valued at approximately $876,846 under a pre-arranged Rule 10b5-1 trading plan. He retained 236,527 shares, making the transaction a limited sentiment concern rather than a clear signal of deteriorating company prospects. CFO stock sale article
• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action against Hims & Hers and certain executives. The allegations stem from the FTC’s complaint concerning privacy practices, subscription cancellations and prescription billing, with investors claiming the company failed to disclose material risks. The deadline to seek lead-plaintiff status is November 2, 2026. Potential legal costs, reputational damage and regulatory remedies are weighing on the investment case. Hims & Hers securities class action article
• Negative Sentiment: Profitability is another vulnerability: the latest reported quarter included a $0.37-per-share loss versus an expected $0.05 loss, despite revenue of $753.2 million exceeding estimates. High short interest and elevated volatility may amplify market reactions to further legal, regulatory or earnings developments. Hims & Hers legal pressure and stock decline article

Hims & Hers Health Stock Performance

Shares of HIMS opened at $29.46 on Friday. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $65.30. The company has a market cap of $6.87 billion, a price-to-earnings ratio of -46.76 and a beta of 2.42. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The firm has a fifty day moving average of $29.54 and a 200-day moving average of $28.07.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm's revenue was up 38.2% on a year-over-year basis. During the same period last year, the business earned $0.17 EPS. As a group, equities analysts anticipate that Hims & Hers Health will post -0.16 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 29,277 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $29.95, for a total transaction of $876,846.15. Following the sale, the chief financial officer directly owned 236,527 shares in the company, valued at $7,083,983.65. The trade was a 11.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the company's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05. Following the completion of the sale, the insider directly owned 313,964 shares of the company's stock, valued at $8,649,708.20. The trade was a 7.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 128,684 shares of company stock worth $3,731,869. Insiders own 11.76% of the company's stock.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its stake in shares of Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock worth $90,465,000 after acquiring an additional 2,877,550 shares during the period. Norges Bank acquired a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $62,153,000. Bank of New York Mellon Corp acquired a new position in shares of Hims & Hers Health during the second quarter valued at approximately $46,220,000. Bienville Capital Management LLC bought a new stake in Hims & Hers Health during the second quarter worth approximately $27,242,000. Finally, Principal Financial Group Inc. raised its holdings in Hims & Hers Health by 97.3% during the first quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company's stock worth $26,620,000 after purchasing an additional 632,282 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men's health before expanding under the Hers brand to serve women and broaden its health-care offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.